CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    UL54

    Mutations:

    Mutant Antiviral EC50 ratio Phenotype Assay Reference
    N4H Natural polymorphism Details
    N4Y Natural polymorphism Details
    S8N Natural polymorphism Details
    S8T Natural polymorphism Details
    A15S Natural polymorphism Details
    A17P Natural polymorphism Details
    R21C Natural polymorphism Details
    S24L Natural polymorphism Details
    S32P Natural polymorphism Details
    V95E Natural polymorphism Details
    H142Y Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G143S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    D163H Natural polymorphism Details
    Q229K Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q229K Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q229K Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E235G Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T242K Natural polymorphism Details
    D247N Ganciclovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N Foscarnet 1.30 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    C256S Natural polymorphism Details
    C256L Natural polymorphism Details
    D262N Ganciclovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N267Y Natural polymorphism Details
    A269V Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A Cidofovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D284E Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N Cidofovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S290R Cidofovir 1.30 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R Cidofovir 1.40 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R Foscarnet 2.20 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R Foscarnet 2.30 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R Ganciclovir 1.50 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R Ganciclovir 1.70 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    D301N Ganciclovir 2.60 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D301N Cidofovir 3.00 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D301N Foscarnet 0.50 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E303G Brincidofovir 11.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G Cidofovir 20.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G Ganciclovir 7.30 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G Foscarnet 0.80 No resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D Brincidofovir 9.70 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D Cidofovir 16.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D Ganciclovir 6.30 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D Foscarnet 0.80 No resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    A336T Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I341T Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N345S Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G347D Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    T351A Natural polymorphism Details
    V355A Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    F357I Natural polymorphism Details
    P375L Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Y380C Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L394F Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L Ganciclovir 1.40 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L Cidofovir 1.50 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L Foscarnet 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N408D Ganciclovir 4.90 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    N408D Cidofovir 5.60 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    N408D Foscarnet 1.30 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    N408H Ganciclovir 2.00 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H Cidofovir 3.30 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H Foscarnet 3.00 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408K Ganciclovir 4.20 Intermediate level resistance Details Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K Cidofovir 21.00 High level resistance Details Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K Foscarnet 0.70 No resistance Details Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K Brincidofovir 11.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    N408S Ganciclovir 3.10 Intermediate level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S Cidofovir 7.50 High level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N408S Foscarnet 1.00 No resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    N410K Ganciclovir 2.90 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    N410K Cidofovir 3.00 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    N410K Foscarnet 0.80 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    F412C Ganciclovir 4.20 Intermediate level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412C Cidofovir 18.00 High level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412C Foscarnet 1.20 No resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412L Ganciclovir 4.60 Intermediate level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412L Cidofovir 9.40 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412L Foscarnet 1.10 No resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S Ganciclovir 5.30 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S Cidofovir 13.00 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S Foscarnet 0.80 No resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412V Ganciclovir 4.30 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    F412V Cidofovir 15.50 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    F412V Foscarnet 1.10 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D413A Ganciclovir 6.50 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413A Cidofovir 11.00 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413A Foscarnet 0.80 No resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413E Ganciclovir 4.80 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413E Cidofovir 4.30 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413E Foscarnet 0.80 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413N Ganciclovir 3.80 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413N Cidofovir 10.00 High level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413N Foscarnet 1.00 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413del Brincidofovir 5.20 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del Cidofovir 5.80 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del Ganciclovir 3.80 Intermediate level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del Foscarnet 1.30 No resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y Brincidofovir 6.00 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y Cidofovir 9.30 High level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y Ganciclovir 4.40 Intermediate level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y Foscarnet 1.00 No resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    L424V Ganciclovir 1.30 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V Cidofovir 1.30 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K426R Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K426E Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E Cidofovir 0.90 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E Foscarnet 1.10 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E Foscarnet 0.90 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E Ganciclovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E Ganciclovir 1.10 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    G441S Natural polymorphism Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    V450G Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L Cidofovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460S Natural polymorphism Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    S464F Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    H465Y Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N467S Natural polymorphism Details
    A469T Natural polymorphism Details
    A473V Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G Ganciclovir 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G Foscarnet 0.40 Possible hypersensitivity, no resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V482G Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V483A Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P488R Ganciclovir 3.50 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P488R Cidofovir 7.90 High level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P488R Foscarnet 0.60 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A492D Ganciclovir 1.35 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    A492D Cidofovir 1.36 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    A492D Foscarnet 1.45 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    N495K Ganciclovir 1.10 No resistance Details A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K Cidofovir 1.10 No resistance Details A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K Foscarnet 3.40 Intermediate level resistance Details A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. ( 2006)
    N495K Cidofovir 1.20 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K Foscarnet 2.50 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K Foscarnet 2.60 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K Ganciclovir 1.30 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K Ganciclovir 1.40 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    P497S Cidofovir 2.40 Low level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    P497S Foscarnet 0.80 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    P497S Ganciclovir 1.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    N498S Cidofovir 1.80 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    N498S Foscarnet 1.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    N498S Ganciclovir 1.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    K500N Ganciclovir 3.20 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N Cidofovir 3.00 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N Foscarnet 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L501F Ganciclovir 2.60 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F Cidofovir 3.80 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F Foscarnet 1.30 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501I Ganciclovir 6.00 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L501I Cidofovir 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L501I Foscarnet 1.40 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T503A Ganciclovir 3.10 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A Cidofovir 3.70 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A Foscarnet 1.50 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503I Ganciclovir 2.90 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    T503I Cidofovir 6.10 High level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    T503I Foscarnet 0.50 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    A505V Ganciclovir 1.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A505V Cidofovir 2.00 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A505V Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R512C Natural polymorphism Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    K513E Ganciclovir 5.00 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K513E Cidofovir 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K513E Foscarnet 1.40 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K513N Ganciclovir 6.00 High level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    K513N Cidofovir 12.50 High level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    K513N Foscarnet 1.50 No resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    K513Q Ganciclovir 6.60 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q Cidofovir 18.00 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q Foscarnet 1.00 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513R Ganciclovir 3.70 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    K513R Cidofovir 10.00 High level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    K513R Foscarnet 1.10 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D515G Natural polymorphism Details
    D515E Ganciclovir 2.70 Low level resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    D515E Cidofovir 1.60 No resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    D515E Foscarnet 4.60 Intermediate level resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    D515E Cidofovir 1.10 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515E Foscarnet 0.90 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515E Ganciclovir 1.00 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515Y Ganciclovir 6.20 High level resistance Details Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y Cidofovir 0.87 No resistance Details Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y Foscarnet 4.70 Intermediate level resistance Details Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. (May 2016)
    D515Y Cidofovir 2.60 Low level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D515Y Foscarnet 1.10 No resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D515Y Ganciclovir 3.20 Intermediate level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    L516R Ganciclovir 2.10 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516R Cidofovir 5.10 High level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516R Foscarnet 0.80 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516W Ganciclovir 4.20 Intermediate level resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    L516W Cidofovir 8.49 High level resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    L516W Foscarnet 1.22 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    Y518C Natural polymorphism Details
    I521T Ganciclovir 2.10 Low level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    I521T Cidofovir 5.10 High level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    I521T Foscarnet 0.80 No resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A Ganciclovir 3.00 Intermediate level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A Cidofovir 4.10 Intermediate level resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A Foscarnet 1.00 No resistance Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522L Natural polymorphism Details Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522S Ganciclovir 3.10 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    P522S Cidofovir 3.60 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    P522S Foscarnet 1.10 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    P522T Ganciclovir 2.10 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T Cidofovir 2.00 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T Foscarnet 1.40 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C524del Ganciclovir 3.50 Intermediate level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del Cidofovir 9.70 High level resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    C524del Foscarnet 1.10 No resistance Details Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (Apr 2013)
    V526L Ganciclovir 5.50 High level resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    V526L Cidofovir 2.50 Low level resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    V526L Foscarnet 1.80 No resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    C539G Ganciclovir 3.10 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G Cidofovir 4.40 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G Foscarnet 1.00 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539R Ganciclovir 3.20 Intermediate level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    C539R Cidofovir 13.30 High level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    C539R Foscarnet 0.70 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    Q541P Natural polymorphism Details
    D542E Ganciclovir 1.50 No resistance Details Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    D542E Cidofovir 12.00 High level resistance Details Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    D542E Foscarnet 1.70 No resistance Details Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. (Jul 2013)
    D542E Cidofovir 13.00 High level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D542E Foscarnet 0.50 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D542E Ganciclovir 3.50 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V Cidofovir 10.00 High level resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A543V Cidofovir 3.20 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V Foscarnet 0.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V Ganciclovir 2.10 Low level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543S Ganciclovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543S Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543S Foscarnet 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L545F Ganciclovir 4.00 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F Cidofovir 11.00 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F Foscarnet 1.20 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545S Ganciclovir 3.50 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L545S Cidofovir 9.10 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L545S Foscarnet 1.20 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    L545W Ganciclovir 4.90 Intermediate level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    L545W Cidofovir 6.30 High level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    L545W Foscarnet 1.30 No resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    T552S Foscarnet 0.50 No resistance Details Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552S Ganciclovir 3.00 Intermediate level resistance Details Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552S Cidofovir 2.70 Low level resistance Details Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient. (May 2022)
    T552N Ganciclovir 1.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N Cidofovir 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N Foscarnet 2.60 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N Cidofovir 1.70 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N Foscarnet 2.50 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N Foscarnet 3.10 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N Ganciclovir 1.80 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N Ganciclovir 2.60 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    L565V Cidofovir 1.60 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    L565V Foscarnet 3.70 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    L565V Ganciclovir 1.80 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    Q578H Ganciclovir 3.30 Intermediate level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H Cidofovir 2.30 Low level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H Foscarnet 4.50 Intermediate level resistance Details Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578L Ganciclovir 1.90 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    Q578L Cidofovir 0.80 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    Q578L Foscarnet 3.00 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    R581H Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S585A Ganciclovir 1.50 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    S585A Cidofovir 1.40 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    S585A Foscarnet 2.70 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    D588E Ganciclovir 1.30 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D588E Cidofovir 1.10 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D588E Foscarnet 2.30 Low level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    D588N Ganciclovir 3.80 Intermediate level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    D588N Cidofovir 2.70 Low level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    D588N Foscarnet 3.20-9.00 Range of values between Intermediate level resistance and High level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    C590F Ganciclovir 1.60 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F Cidofovir 1.60 No resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F Foscarnet 2.30 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    D594N Cidofovir 1.00 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D594N Foscarnet 1.00 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D594N Ganciclovir 1.00 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    F595I Ganciclovir 1.30 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I Cidofovir 1.20 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I Foscarnet 2.00 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    G604S Natural polymorphism Details
    S612N Natural polymorphism Details
    P617S Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I622L Natural polymorphism Details
    I622L Natural polymorphism Details Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. (Apr 2010)
    A626V Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P628A Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P628L Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G629S Natural polymorphism Details
    A631G Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S633F Natural polymorphism Details
    V634A Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M640R Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A647S Natural polymorphism Details
    S651E Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G653S Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G Ganciclovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G Cidofovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S655L Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S660G Ganciclovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660N Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S663N Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G667N Ganciclovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N Cidofovir 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N Foscarnet 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F669L Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S676G Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G678S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V681del Natural polymorphism Details
    N685S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    H686Y Natural polymorphism Details
    A688V Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G689R Natural polymorphism Details
    T691S Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T691A Natural polymorphism Details
    T691A Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692V Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692S Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G Ganciclovir 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G Foscarnet 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692F Natural polymorphism Details
    A693T Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S695T Natural polymorphism Details
    Q697H Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    T700A Ganciclovir 0.90 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T700A Cidofovir 1.50 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T700A Foscarnet 4.70 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    V715A Ganciclovir 1.77 No resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715A Cidofovir 0.47 Possible hypersensitivity, no resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715A Foscarnet 2.50 Low level resistance Details Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance. (Jul 2016)
    V715M Ganciclovir 1.00 No resistance Details Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    V715M Cidofovir 1.10 No resistance Details Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    V715M Foscarnet 5.50 High level resistance Details Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    F718L Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F718S Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I722V Natural polymorphism Details
    I726T Ganciclovir 2.00 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T Cidofovir 1.70 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V Ganciclovir 1.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V Cidofovir 1.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L737M Natural polymorphism Details
    E756D Ganciclovir 1.20 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756D Cidofovir 0.70 No resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756D Foscarnet 3.40 Intermediate level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K Ganciclovir 2.50 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K Cidofovir 2.20 Low level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K Foscarnet >8.00 At least High level resistance Details Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756Q Ganciclovir 1.70 No resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    E756Q Cidofovir 1.00 No resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    E756Q Foscarnet 4.30 Intermediate level resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    V759M Natural polymorphism Details
    L773V Ganciclovir 3.00 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L773V Cidofovir 2.50 Low level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L773V Foscarnet 4.40 Intermediate level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L776M Ganciclovir 2.50 Low level resistance Details Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    L776M Cidofovir 1.00 No resistance Details Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    L776M Foscarnet 3.50 Intermediate level resistance Details Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    V781I Ganciclovir 1.00-4.00 Range of values between No resistance and Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    V781I Cidofovir 1.20 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    V781I Foscarnet 4.00-5.20 Range of values between Intermediate level resistance and High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    Q783R Cidofovir 0.90 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R Foscarnet 1.70 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R Ganciclovir 1.80 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R Ganciclovir 1.30 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A786V Cidofovir 1.00 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786V Foscarnet 1.10 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786V Ganciclovir 1.00 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786P Natural polymorphism Details
    V787A Ganciclovir 2.50 Low level resistance Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    V787A Cidofovir Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    V787A Foscarnet 3.50 Intermediate level resistance Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    V787E Ganciclovir 8.60 High level resistance Details Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787E Cidofovir 2.90 Low level resistance Details Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787E Foscarnet 3.40 Intermediate level resistance Details Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787L Ganciclovir 2.40 Low level resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    V787L Cidofovir 1.00 No resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    V787L Foscarnet 4.10 Intermediate level resistance Details Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    R792S Natural polymorphism Details
    E793V Ganciclovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E793V Cidofovir 0.70 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E793V Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P Ganciclovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R Ganciclovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R Foscarnet 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V798A Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A Cidofovir 1.10 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A Foscarnet 1.70 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A Foscarnet 1.80 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A Ganciclovir 1.50 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    R800C Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L802M Ganciclovir 1.10-3.50 Range of values between No resistance and Intermediate level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802M Cidofovir 0.90-1.80 Range of values of No resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802M Foscarnet 3.20-10.80 Range of values between Intermediate level resistance and High level resistance Details Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802V Ganciclovir 1.80 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L802V Cidofovir 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L802V Foscarnet 0.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K805Q Ganciclovir 1.00 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K805Q Cidofovir 2.20 Low level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    K805Q Foscarnet 0.18 Possible hypersensitivity, no resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A809V Ganciclovir 2.60 Low level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V Cidofovir 1.70 No resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V Foscarnet 6.30 High level resistance Details Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V Foscarnet 3.60 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A809V Foscarnet 4.40 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V812L Ganciclovir 2.50 Low level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    V812L Cidofovir 3.20 Intermediate level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    V812L Foscarnet 2.90 Low level resistance Details A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. (Sep 1998)
    V812L Brincidofovir 2.40 Low level resistance Details Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    T813S Ganciclovir 2.50 Low level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T813S Cidofovir 2.90 Low level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T813S Foscarnet 4.90 Intermediate level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T821I Ganciclovir 4.50 Intermediate level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T821I Cidofovir 1.90 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    T821I Foscarnet 21.00 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    G822D Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V823A Cidofovir 3.60 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    V823A Foscarnet 0.50 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    V823A Ganciclovir 2.40 Low level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    M827I 0.80 No resistance Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I Cidofovir 0.70 No resistance Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I Ganciclovir Natural polymorphism Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I Foscarnet Natural polymorphism Details Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M828V Non-viable Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P829S Ganciclovir 2.00 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P829S Cidofovir 1.60 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P829S Foscarnet 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A834P Ganciclovir 5.40 High level resistance Details Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004)
    A834P Cidofovir 3.00 Intermediate level resistance Details Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004)
    A834P Foscarnet 6.40 High level resistance Details Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. (Sep 2004)
    T838A Ganciclovir 1.80 No resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    T838A Cidofovir 0.80 No resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    T838A Foscarnet 2.40 Low level resistance Details How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    G841A Ganciclovir 3.20 Intermediate level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841A Cidofovir 2.60 Low level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841A Foscarnet 4.30 Intermediate level resistance Details Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841S Ganciclovir 2.20 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841S Cidofovir 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841S Foscarnet 2.10 Low level resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M844T Ganciclovir 1.40 No resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844T Cidofovir 1.30 No resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844T Foscarnet 2.50 Low level resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V Ganciclovir 2.50 Low level resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V Cidofovir 1.60 No resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V Foscarnet 2.20 Low level resistance Details Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    R847H Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N855D Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A Ganciclovir 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A Foscarnet 0.80 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L862F Ganciclovir 1.70 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L862F Cidofovir 0.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L862F Foscarnet 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    H863R Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q868R Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    D870H Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V873L Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G874R Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in884T Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A885S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A885T Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in885S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in885T Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P887S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L890F Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L890S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    T892I Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S897L Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N898D Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    E899K Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V902G Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G Foscarnet 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E903G Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G920S Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V927M Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A928T Ganciclovir >3.00 At least Intermediate level resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A928T Cidofovir >3.00 At least Intermediate level resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A928T Foscarnet >3.00 At least Intermediate level resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    A928T Cidofovir 1.00 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A928T Foscarnet 0.90 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A928T Ganciclovir 0.90 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    S932N Natural polymorphism Details
    V946L Ganciclovir 1.10 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V946L Cidofovir 0.90 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V946L Foscarnet 2.40 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K947E Ganciclovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K947E Cidofovir 1.00 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K947E Foscarnet 1.10 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E949K Cidofovir 1.60 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K Foscarnet 5.80 High level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K Ganciclovir 1.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q Cidofovir 1.70 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q Foscarnet 3.70 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q Ganciclovir 1.40 No resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E951D Cidofovir 1.00 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D Cidofovir 1.20 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D Foscarnet 3.90 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D Foscarnet 4.40 Intermediate level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D Ganciclovir 2.20 Low level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D Ganciclovir 1.80 No resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V953A Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    R954H Natural polymorphism Details
    S956Y Natural polymorphism Details
    L957F Ganciclovir 2.70 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L957F Cidofovir 1.40 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L957F Foscarnet 1.30 No resistance Details Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    M959T Ganciclovir 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M959T Cidofovir 0.90 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M959T Foscarnet 1.20 No resistance Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A972V Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D981del Ganciclovir 8.30 High level resistance Details A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    D981del Cidofovir 2.80 Low level resistance Details A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    D981del Foscarnet 3.60 Intermediate level resistance Details A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    981-982del Ganciclovir 6.70 High level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del Cidofovir 4.20 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del Foscarnet 3.00 Intermediate level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    A987V Cidofovir 0.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    A987V Foscarnet 3.10 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    A987V Ganciclovir 0.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    A987G Ganciclovir 5.30 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A987G Cidofovir 11.30 High level resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A987G Foscarnet 1.20 No resistance Details Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. (Jul 1998)
    A987G Cidofovir 8.50 High level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A987G Cidofovir 5.00 High level resistance Details Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E989D Cidofovir 1.90 No resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    E989D Foscarnet 5.70 High level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    E989D Ganciclovir 3.20 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    E989Q Natural polymorphism Details
    G993C Natural polymorphism Details
    T995K Natural polymorphism Details
    N998D Natural polymorphism Details
    S1000L Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D1005N Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R1006C Natural polymorphism Details Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R1006G Natural polymorphism Details
    A1012V Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L1020I Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    R1052C Natural polymorphism Details
    D1055L Natural polymorphism Details
    R1070G Natural polymorphism Details
    Q1071R Natural polymorphism Details
    L1074M Natural polymorphism Details
    V1079I Natural polymorphism Details
    T1108A Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N1116H Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A1122T Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P1129Q Natural polymorphism Details
    G1133S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A1138T Natural polymorphism Details
    S1146N Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N1147S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    R1149T Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G1151del Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P1153S Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L1156del Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1162L Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1235T Natural polymorphism Details Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    C1241G Natural polymorphism Details
    D981del2 Cidofovir 3.20 Intermediate level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D981del2 Cidofovir 3.20 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 Cidofovir 3.70 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D981del2 Foscarnet 2.70 Low level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D981del2 Foscarnet 3.00 Intermediate level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 Foscarnet 3.10 Intermediate level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D981del2 Ganciclovir 7.00 High level resistance Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D981del2 Ganciclovir 7.50 High level resistance Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 Ganciclovir 6.20 High level resistance Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230